Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT00897533 · clinicaltrials.gov ↗

COMPLETED

Status

137

Enrollment

NETWORK

Sponsor class

Conditions

Lung Cancer

Interventions

GENETIC: gene mapping
GENETIC: polymorphism analysis
OTHER: diagnostic laboratory biomarker analysis
OTHER: immunohistochemistry staining method

Sponsor

ECOG-ACRIN Cancer Research Group

Collaborators

[object Object]